ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.254,18
1,03%
S&P 500
5.489,34
0,04%
Dow Jones
38.942,27
0,28%
Euro vs US Dollar
1,07091
-0,36%
Bitcoin
64.740,78
-0,36%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Immunovant Inc (IMVT)

  7. Immunovant Inc (IMVT) News

IMVT

Immunovant (IMVT)

Immunovant Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:IMVT
DatumZeitQuelleÜberschriftSymbolFirma
29/05/202422h36Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:IMVTImmunovant Inc
29/05/202422h17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMVTImmunovant Inc
29/05/202422h01GlobeNewswire Inc.Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024NASDAQ:IMVTImmunovant Inc
24/05/202422h18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMVTImmunovant Inc
24/05/202422h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMVTImmunovant Inc
24/05/202422h14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMVTImmunovant Inc
24/05/202422h13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMVTImmunovant Inc
12/03/202412h30GlobeNewswire Inc.Immunovant Awarded U.S. Patent for IMVT-1402NASDAQ:IMVTImmunovant Inc
23/02/202422h21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMVTImmunovant Inc
23/02/202422h16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMVTImmunovant Inc
23/02/202422h11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMVTImmunovant Inc
14/02/202414h47Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:IMVTImmunovant Inc
12/02/202413h05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IMVTImmunovant Inc
12/02/202413h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMVTImmunovant Inc
29/01/202422h11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMVTImmunovant Inc
19/01/202422h04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMVTImmunovant Inc
16/01/202413h29Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IMVTImmunovant Inc
12/01/202422h34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMVTImmunovant Inc
09/01/202422h20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMVTImmunovant Inc
09/01/202422h18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMVTImmunovant Inc
09/01/202414h08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMVTImmunovant Inc
03/01/202414h00GlobeNewswire Inc.Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:IMVTImmunovant Inc
20/12/202323h40Dow Jones NewsImmunovant Gets Positive Data From Graves' Disease Treatment TrialNASDAQ:IMVTImmunovant Inc
20/12/202322h37Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMVTImmunovant Inc
20/12/202322h30GlobeNewswire Inc.Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ DiseaseNASDAQ:IMVTImmunovant Inc
20/12/202322h30GlobeNewswire Inc.Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ DiseaseNASDAQ:IMVTImmunovant Inc
28/11/202313h43Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMVTImmunovant Inc
28/11/202313h00GlobeNewswire Inc.Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class PotentialNASDAQ:IMVTImmunovant Inc
28/11/202313h00GlobeNewswire Inc.Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class PotentialNASDAQ:IMVTImmunovant Inc
24/11/202320h55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMVTImmunovant Inc
 Showing the most relevant articles for your search:NASDAQ:IMVT

Kürzlich von Ihnen besucht

AMEX
XLE
Energy Select Sector SPDR
AMEX
XLF
Financial Select Sector
USOTC
RHHBY
Roche (QX)
TG
DBK
Deutsche Bank
PM
XAUUSD
Gold vs US Dollar
FX
EURUSD
Euro vs US Dollar
NYSE
JPM
JP Morgan Chase
COIN
BTCUSD
Bitcoin
NYSE
DIS
Walt Disney
NYSE
KO
Coca Cola
USOTC
BNPQY
BNP Paribas (QX)
CCOM
US100
US Tech 100
NASDAQ
MSFT
Microsoft
DBI
SDXP
SDAX
TG
ALV
Allianz
CCOM
US30
US 30
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten